(Public, NASDAQ:OXGN)   Watch this stock  
Find more results for OXGN
+0.025 (3.94%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.63 - 0.68
52 week 0.49 - 1.68
Open 0.63
Vol / Avg. 352,676.00/801,489.00
Mkt cap 18.21M
P/E     -
Div/yield     -
EPS -0.54
Shares 26.54M
Beta 2.38
Inst. own 8%
Aug 2, 2016
Q2 2016 OXiGENE Inc Earnings Release (Estimated) Add to calendar
May 9, 2016
Q1 2016 OXiGENE Inc Earnings Release
Mar 28, 2016
Q4 2015 OXiGENE Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -51.60% -47.18%
Return on average equity -56.07% -50.24%
Employees 13 -
CDP Score - -


701 Gateway Blvd Ste 210
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OXiGENE, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively target the vasculature of cancer tumors and obstruct a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). The Company has been granted orphan drug designation for CA4P for the treatment of ovarian cancer and for OXi4503 for the treatment of acute myelogenous leukemia (AML), in the United States and the European Union. The OXi4503 is a dual-mechanism VDA.

Officers and directors

Frederick W. Driscoll Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
William D. Schwieterman M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Matthew M. Loar CPA Chief Financial Officer, Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Bio & Compensation  - Reuters
Simon C. Pedder Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Gerald McMahon Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters